Brief: Synaptogenix Announces Topline Results From NIH-Sponsored Phase 2 Clinical Trial Of Bryostatin-1 For Advanced Alzheimer's Disease

TAO Synergies

16/12/2022 15:13

Dec 16 (Reuters) - Synaptogenix Inc  SNPX.O :
    * SYNAPTOGENIX ANNOUNCES TOPLINE RESULTS FROM NIH-SPONSORED
PHASE
2 CLINICAL TRIAL OF BRYOSTATIN-1 FOR ADVANCED ALZHEIMER'S
DISEASE
    * SYNAPTOGENIX INC -  TRIAL'S PRIMARY ENDPOINT WAS NOT MET
WITH
STATISTICAL SIGNIFICANCE
    * SYNAPTOGENIX - AVERAGE INCREASE IN SIB TOTAL SCORE OF 1.4
POINTS
AND 0.6 POINTS OBSERVED FOR BRYOSTATIN-1 AND PLACEBO GROUPS,
RESPECTIVELY, AT WEEK 28
    * SYNAPTOGENIX INC - SYNAPTOGENIX REMAINS WELL-FUNDED WITH
APPROXIMATELY $38.5 MILLION IN CASH AS OF DECEMBER 15, 2022

Source text for Eikon:  ID:nPn2ZDDMza 
Further company coverage:  SNPX.O 
 ((Reuters.Briefs@thomsonreuters.com;))